Kelyniam Global Announces Q2 2025 Financial Results

Rhea-AI Summary

Kelyniam Global (OTC: KLYG), a manufacturer of custom cranial and craniofacial implants, reported challenging Q2 2025 financial results. The company experienced a 20.2% decrease in revenue to $1,364,432 compared to Q2 2024, with gross margin declining 18.1% to $1,090,691.

The company shifted from an operating profit of $172,093 in Q2 2024 to an operating loss of $59,869 in Q2 2025. Despite these challenges, management highlighted improved Q2 performance compared to Q1, attributing slower periods to the unpredictable nature of the cranial implant market. The company maintains its competitive advantage through 24-48 hour delivery of custom implants for rush cases.

Positive

• Improved quarter-over-quarter performance from Q1 to Q2 2025
• Maintained strong 24-48 hour delivery capability for rush cases
• Record levels of shareholder participation in annual meeting

Negative

• Revenue decreased 20.2% year-over-year to $1.36M in Q2 2025
• Gross margin declined 18.1% compared to Q2 2024
• Shifted from operating profit to loss of $59,869

CANTON, Conn., Aug. 11, 2025 /PRNewswire/ -- Kelyniam Global, Inc. (OTC: KLYG), a leading manufacturer of custom cranial and craniofacial implants, today announced its financial results for the half year ending on June 30, 2025.

"The Company made up significant ground from the difficult comparisons in the first quarter," said Ross Bjella, CEO of Kelyniam. "Kelyniam focused its efforts on sales execution and the 2^nd quarter on quarter results improved nicely over Q1 performance.  The cranial implant market is driven by unforeseeable events and some time periods are busier than others.  Q1 this year was just a slower period and our distributors worked hard to capture as many available opportunities as possible in Q2." 

Q2 2025 Financial Highlights (compared to Q2 2024):

• Total revenue of $1,364,432, compared to $1,709,239, a decrease of 20.2%.
• Gross margin of $1,090,691, compared to $1,330,965, a decrease of 18.1%.
• Operating loss of $(59.869), compared to an operating profit of $172,093.

Desiree Webb, Kelyniam's Chief Operating and Revenue Officer said, "Kelyniam's unique advantage of delivering complex custom cranial and craniofacial implants within 24-48 hours for rush and expedited cases allows us to pivot quickly for surgeons, sales reps and distributors. The Company experienced greater sales over the prior year in the latter part of Q2 in part to a laser focus on sales as we head into the trauma season."

The Company held its annual shareholder meeting on June 23^rd and all matters of official business passed with record levels of participation.

Kelyniam's complete financial results are available at www.kelyniam.com.

About Kelyniam Global, Inc. 
Kelyniam Global, Inc. designs, manufactures, and distributes custom cranial and craniofacial implants using biocompatible materials. Known for its rapid 24-48 hour delivery, Kelyniam collaborates with surgeons and healthcare providers to improve clinical outcomes. Learn more at www.kelyniam.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, including those regarding future sales, distributor expansion, and the impact of strategic partnerships, involve risks and uncertainties that could cause actual results to differ materially from those projected. Such risks include economic conditions, competitive pressures, regulatory changes, and challenges in executing sales strategies, as detailed in Kelyniam's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Kelyniam undertakes no obligation to update these statements except as required by law.

View original content:https://www.prnewswire.com/news-releases/kelyniam-global-announces-q2-2025-financial-results-302526567.html

SOURCE Kelyniam Global Inc

FAQ

What were Kelyniam Global's (KLYG) Q2 2025 earnings results?

Kelyniam reported Q2 2025 revenue of $1,364,432, down 20.2% year-over-year, with an operating loss of $59,869 compared to a profit of $172,093 in Q2 2024.

How much did Kelyniam's (KLYG) gross margin decline in Q2 2025?

Kelyniam's gross margin decreased by 18.1% to $1,090,691 compared to $1,330,965 in Q2 2024.

What is Kelyniam's competitive advantage in the cranial implant market?

Kelyniam's key advantage is its ability to deliver custom cranial and craniofacial implants within 24-48 hours for rush and expedited cases.

Why did Kelyniam (KLYG) experience lower sales in Q2 2025?

The company attributed lower sales to the unpredictable nature of the cranial implant market, with some periods being slower than others due to unforeseeable events.

How did Kelyniam perform in Q2 2025 compared to Q1 2025?

According to management, Kelyniam showed improved performance in Q2 compared to Q1, with increased sales focus heading into the trauma season.